Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With Gout.
Journal
Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
19
09
2022
received:
13
05
2022
accepted:
18
10
2022
medline:
17
5
2023
pubmed:
26
10
2022
entrez:
25
10
2022
Statut:
ppublish
Résumé
To determine whether a gout polygenic risk score (PRS) is associated with age at gout onset and tophaceous disease in European, East Polynesian, and West Polynesian men and women with gout. A 19-variant gout PRS was produced in 7 European gout cohorts (N = 4,016), 2 East Polynesian gout cohorts (N = 682), and 1 West Polynesian gout cohort (N = 490). Sex-stratified regression models were used to estimate the relationship between the PRS and age at gout onset and tophaceous disease. The PRS was associated with earlier age at gout onset in men (β = -3.61 in years per unit PRS [95% confidence interval (95% CI) -4.32, -2.90] in European men; β = -6.35 [95% CI -8.91, -3.80] in East Polynesian men; β = -3.51 [95% CI -5.46, -1.57] in West Polynesian men) but not in women (β = 0.07 [95% CI -2.32, 2.45] in European women; β = 0.20 [95% CI -7.21, 7.62] in East Polynesian women; β -3.33 [95% CI -9.28, 2.62] in West Polynesian women). The PRS showed a positive association with tophaceous disease in men (odds ratio [OR] for the association 1.15 [95% CI 1.00, 1.31] in European men; OR 2.60 [95% CI 1.66, 4.06] in East Polynesian men; OR 1.53 [95% CI 1.07, 2.19] in West Polynesian men) but not in women (OR for the association 0.68 [95% CI 0.42, 1.10] in European women; OR 1.45 [95% CI 0.39, 5.36] in East Polynesian women). The PRS association with age at gout onset was robust to the removal of ABCG2 variants from the PRS in European and East Polynesian men (β = -2.42 [95% CI -3.37, -1.46] and β = -6.80 [95% CI -10.06, -3.55], respectively) but not in West Polynesian men (β = -1.79 [95% CI -4.74, 1.16]). Genetic risk variants for gout also harbor risk for earlier age at gout onset and tophaceous disease in European and Polynesian men. Our findings suggest that earlier gout onset involves the accumulation of gout risk alleles in men but perhaps not in women, and that this genetic risk is shared across multiple ancestral groups.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
816-825Informations de copyright
© 2022 American College of Rheumatology.
Références
Zhang B, Fang W, Zeng X, et al. Clinical characteristics of early- and late-onset gout: a cross-sectional observational study from a Chinese gout clinic. Medicine (Baltimore) 2016;95:e5425.
Pascart T, Norberciak L, Ea HK, et al. Patients with early-onset gout and development of earlier severe joint involvement and metabolic comorbid conditions: results from a cross-sectional epidemiologic survey. Arthritis Care Res (Hoboken) 2019;71:986-992.
Kuo CF, Grainge MJ, Zhang W, et al. Global epidemiology of gout: prevalence, incidence and risk factors [review]. Nat Rev Rheumatol 2015,;1:649-62.
Zaidi F, Narang RK, Phipps-Green A, et al. Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus. Rheumatology (Oxford) 2020;59:2544-9.
He W, Phipps-Green A, Stamp LK, et al. Population-specific association between ABCG2 variants and tophaceous disease in people with gout. Arthritis Res Ther 2017;19:43.
Matsuo H, Ichida K, Takada T, et al. Common dysfunctional variants in ABCG2 are a major cause of early-onset gout. Sci Rep 2013;3:2014.
Hirsch JD, Terkeltaub R, Khanna D, et al. Gout disease-specific quality of life and the association with gout characteristics. Patient Relat Outcome Meas 2010;2010:1-8.
Perez-Ruiz F, Martínez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis 2014;73:177-182.
Tin A, Marten J, Halperin Kuhns VL, et al. Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nat Genet 2019;51:1459-74.
Bodofsky S, Merriman TR, Thomas TJ, et al. Advances in our understanding of gout as an auto-inflammatory disease [review]. Semin Arthritis Rheum 2020;50:1089-100.
Major TJ, Dalbeth N, Stahl EA, et al. An update on the genetics of hyperuricaemia and gout [review]. Nat Rev Rheumatol 2018;14:341-53.
Sham PC, Purcell SM. Statistical power and significance testing in large-scale genetic studies [review]. Nat Rev Genet 2014;15:335-46.
Elliott J, Bodinier B, Bond TA, et al. Predictive accuracy of a polygenic risk score-enhanced prediction model vs a clinical risk score for coronary artery disease. JAMA 2020;323:636-45.
Peterson RE, Kuchenbaecker K, Walters RK, et al. Genome-wide association studies in ancestrally diverse populations: opportunities, methods, pitfalls, and recommendations [review]. Cell 2019;179:589-603.
Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 2018;562:203-9.
Becker MA, Fitz-Patrick D, Choi HK, et al. An open-label, 6-month study of allopurinol safety in gout: the LASSO study. Semin Arthritis Rheum 2015;45:174-83.
Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study) [published correction appears in Arthritis Rheumatol 2018;70:1318]. Arthritis Rheumatol 2017;69:203-12.
Bardin T, Keenan RT, Khanna PP, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis 2017;76:811-20.
Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheumatol 2017;69:1903-13.
Tausche AK, Alten R, Dalbeth N, et al. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology (Oxford) 2017;56:2170-8.
Ji A, Shaukat A, Takei R, et al. Aotearoa New Zealand Māori and Pacific population-amplified gout risk variants: CLNK is a separate risk gene at the SLC2A9 locus. J Rheumatol 2021;48:1736-44.
Krishnan M, Major TJ, Topless RK, et al. Discordant association of the CREBRF rs373863828 A allele with increased BMI and protection from type 2 diabetes in Māori and Pacific (Polynesian) people living in Aotearoa/New Zealand. Diabetologia 2018;61:1603-13.
Chen WM. KING tutorial: relationship inference. 2022. Accessed February 13, 2023. URL: https://www.kingrelatedness.com/manual.shtml.
Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-75.
R Foundation. The R project for statistical computing; 2022. Accessed January 27, 2023. URL: https://www.r-project.org/.
Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 2019;22:153-60.
Richette P, Clerson P, Périssin L, et al. Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis 2015;74:142-7.
Te Kampe R, Janssen M, van Durme C, et al. Sex differences in the clinical profile among patients with gout: cross-sectional analyses of an observational study. J Rheumatol 2021;48:286-92.
Hak AE, Curhan GC, Grodstein F, et al. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis 2010;69:1305-9.
Sumpter N, Cadzow M, So A, et al. Analysis of common gout comorbidities in the UK Biobank cohort reveals sex-specific effects and genetic differentiation [abstract]. Arthritis Rheumatol 2020;72 Suppl. URL: https://acrabstracts.org/abstract/analysis-of-common-gout-comorbidities-in-the-uk-biobank-cohort-reveals-sex-specific-effects-and-genetic-differentiation/.
Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum 2020;50 Suppl:S11-6.
Patel AV, Gaffo AL. Managing gout in women: current perspectives [review]. J Inflamm Res 2022;15:1591-8.
Stiburkova B, Pavelcova K, Pavlikova M, et al. The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients. Arthritis Res Ther 2019;21:77.
Choi HK, Nguyen US, Niu J, et al. Selection bias in rheumatic disease research [review]. Nat Rev Rheumatol 2014;10:403-12.
Paternoster L, Tilling K, Davey Smith G. Genetic epidemiology and Mendelian randomization for informing disease therapeutics: conceptual and methodological challenges [review]. PLoS Genet 2017;13:e1006944.
Gaffo AL, Schumacher HR, Saag KG, et al. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum 2012;64:1508-17.
Gaffo AL, Dalbeth N, Saag KG, et al. Validation of a definition of flare in patients with established gout. Arthritis Rheumatol 2018;70:462-7.
Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.